Lyell Immunopharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Lyell Immunopharma generated cash of -$163,694,000, which is more than the previous year. Cash used in financing activities reached the amount of $1,743,000 last year. Net change in cash is therefore $22,097,000.
Cash Flow
| 2019 | 39.47M | -422.43M | 351.15M |
|---|---|---|---|
| 2020 | -160.87M | -273.51M | 476.79M |
| 2021 | -126.24M | -121.57M | 401.24M |
| 2022 | -169.55M | -11.54M | 10.63M |
| 2023 | -163.69M | 184.04M | 1.74M |
LYEL Cash Flow Statement (2019 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
Cash at beginning of period | 123.83M | 294.29M | 140.87M | 98.47M | 130.27M |
Operating activities | |||||
Net income | -234.63M | -183.11M | -250.21M | -204.47M | -129.37M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||
Depreciation and amortization | 20.25M | 18.02M | 13.62M | 4.29M | 1.25M |
Stock-based compensation expense | 47.08M | 81.92M | 62.20M | 33.26M | 15.73M |
| Deferred income tax benefit | 47.08M | 81.92M | 62.20M | 33.26M | 15.73M |
| Changes in operating assets and liabilities: | |||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 1.46M | 667K | 91K | -278K | 1.70M |
Cash generated by operating activities | -163.69M | -169.55M | -126.24M | -160.87M | 39.47M |
Investing activities | |||||
Purchases Of Investments | -476.88M | -406.31M | -673.46M | -43.44M | -34M |
Investments In Property Plant And Equipment | -2.68M | -24.27M | -65.50M | -51.48M | -16.04M |
Acquisitions Net | -186.73M | -12.73M | 673.46M | 0 | 0 |
Cash generated by investing activities | 184.04M | -11.54M | -121.57M | -273.51M | -422.43M |
Financing activities | |||||
Common Stock Issued | 2.2M | 9.57M | 391.80M | 492.84M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -457K | -461K | 0 | -16.05M | -185K |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 1.74M | 10.63M | 401.24M | 476.79M | 351.15M |
Net Change In Cash | 22.09M | -170.46M | 153.42M | 42.4M | -31.80M |
Cash at end of period | 145.93M | 123.83M | 294.29M | 140.87M | 98.47M |
| Data source | Data source |